ArticleJournal of translational medicine2016
Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients.
Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Coordinated suppression of lectin complement pathway effectors and upregulation of SERPING1 defines a thrombo-inflammatory regulatory signature in Acute Coronary disease.Molecular biology reports · 2026Article
- Dialyzer characteristics are associated with differential effects on intradialytic microvascular tissue perfusion.Annals of medicine and surgery (2012) · 2026Article
- Dialysis and cognitive impairment.Nature reviews. Nephrology · 2025Review
- Aminolysis-Based Zwitterionic Immobilization on Polyethersulfone Membranes for Enhanced Hemocompatibility: Experimental, Computational, and Ex Vivo Investigations.Biomimetics (Basel, Switzerland) · 2024Article
- The complement system in lipid-mediated pathologies.Frontiers in immunology · 2024Review
- Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.Cells · 2023Article
- Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.BMC nephrology · 2022Article
- The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?Journal of clinical medicine · 2021Review
- Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function.Journal of nephrology · 2021Article
- End-Stage Renal Disease-Related Accelerated Immune Senescence: Is Rejuvenation of the Immune System a Therapeutic Goal?Frontiers in medicine · 2021Review
- Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay Between Innate and Adaptive Immune Dysfunction.International journal of molecular sciences · 2020Review
- Immunological Effects of a Single Hemodialysis Treatment.Medicina (Kaunas, Lithuania) · 2020Review
- Plasma Complement Protein C3a Level Was Associated with Abdominal Aortic Calcification in Patients on Hemodialysis.Journal of cardiovascular translational research · 2019Article
- The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?Pediatric nephrology (Berlin, Germany) · 2019Article
- Dermal tissue remodeling and non-osmotic sodium storage in kidney patients.Journal of translational medicine · 2019Article
- Administration of Intravenous Iron Formulations Induces Complement ActivationFrontiers in immunology · 2019Article
- Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?Clinical immunology (Orlando, Fla.) · 2019Article
- The Complement System in Dialysis: A Forgotten Story?Frontiers in immunology · 2018Review
- Intradialytic Complement Activation Precedes the Development of Cardiovascular Events in Hemodialysis Patients.Frontiers in immunology · 2018Article
- Coronary Artery Bypass Surgery in End-Stage Renal Disease Patients.Annals of vascular diseases · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemodialysis patients have higher rates of cardiovascular morbidity and mortality compared to the general population. Mannose-binding lectin (MBL) plays an important role in the development of cardiovascular disease. In addition, hemodialysis alters MBL concentration and functional activity. The present study determines the predictive value of MBL levels for future cardiac events (C-event), cardiovascular events (CV-event) and all-cause mortality in HD patients.
methodsWe conducted a prospective study of 107 patients on maintenance hemodialysis. Plasma MBL, properdin, C3d and sC5b-9 was measured before and after one dialysis session. The association with future C-events, CV-events, and all-cause mortality was evaluated using Cox regression models.
resultsDuring median follow-up of 27 months, 36 participants developed 21 C-events and 36 CV-events, whereas 37 patients died. The incidence of C-events and CV-events was significantly higher in patients with low MBL levels (<319 ng/mL, lower quartile). In fully adjusted models, low MBL level was independently associated with increased CV-events (hazard ratio 3.98; 95 % CI 1.88-8.24; P < 0.001) and C-events (hazard ratio 3.96; 95 % CI 1.49-10.54; P = 0.006). No association was found between low MBL levels and all-cause mortality. Furthermore, MBL substantially improved risk prediction for CV-events beyond currently used clinical markers.
conclusionsLow MBL levels are associated with a higher risk for future C-events and CV-events. Therefore, MBL levels may help to identify hemodialysis patients who are at risk to develop cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.